Presentation is loading. Please wait.

Presentation is loading. Please wait.

Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C  Pamela S. Belperio, Elizabeth.

Similar presentations


Presentation on theme: "Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C  Pamela S. Belperio, Elizabeth."— Presentation transcript:

1 Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C  Pamela S. Belperio, Elizabeth W. Hwang, I. Chun Thomas, Larry A. Mole, Ramsey C. Cheung, Lisa I. Backus  Clinical Gastroenterology and Hepatology  Volume 11, Issue 8, Pages (August 2013) DOI: /j.cgh Copyright © 2013 AGA Institute Terms and Conditions

2 Figure 1 Boceprevir and telaprevir on-treatment rates over time.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh ) Copyright © 2013 AGA Institute Terms and Conditions

3 Figure 2 Futility and treatment discontinuation up to week 24 in patients treated with pegylated interferon/ribavirin and either boceprevir or telaprevir: (A) boceprevir, and (B) telaprevir. Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh ) Copyright © 2013 AGA Institute Terms and Conditions


Download ppt "Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C  Pamela S. Belperio, Elizabeth."

Similar presentations


Ads by Google